Jove
Visualize
お問い合わせ
JoVE
x logofacebook logolinkedin logoyoutube logo
JoVEについて
概要リーダーシップブログJoVEヘルプセンター
著者向け
出版プロセス編集委員会範囲と方針査読よくある質問投稿
図書館員向け
推薦の声購読アクセスリソース図書館諮問委員会よくある質問
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experimentsアーカイブ
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教員リソースセンター教員サイト
利用規約
プライバシーポリシー
ポリシー

関連する概念動画

Rheumatic Heart Disease I: Introduction01:23

Rheumatic Heart Disease I: Introduction

797
Rheumatic heart disease or RHD is a chronic condition that results from rheumatic fever, causing permanent damage to the heart valves.Etiology and Risk FactorsIt primarily arises from rheumatic fever, an inflammatory disease that can develop after untreated or inadequately treated group A streptococcal (GAS) pharyngitis. Streptococcus spreads through direct contact with oral or respiratory secretions. While the bacteria are the causative agents, factors like malnutrition, overcrowding, poor...
797
Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies01:22

Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies

958
The key clinical manifestations of Rheumatic heart disease (RHD) include several distinct cardiac symptoms.Carditis, a hallmark of acute rheumatic fever, involves inflammation of the heart's endocardium, myocardium, and pericardium. Chronic RHD often results from recurrent episodes of carditis. Its symptoms include the following:Murmurs are caused by valvular damage, especially to the mitral and aortic valves. Mitral stenosis or regurgitation is common, with characteristic heart murmurs...
958
Genome-wide Association Studies-GWAS01:11

Genome-wide Association Studies-GWAS

16.5K
Genome-wide association studies or GWAS are used to identify whether common SNPs are associated with certain diseases. Suppose specific SNPs are more frequently observed in individuals with a particular disease than those without the disease. In that case, those SNPs are said to be associated with the disease. Chi-square analysis is performed to check the probability of the allele likely to be associated with the disease.
GWAS does not require the identification of the target gene involved in...
16.5K
Rheumatic Heart Disease III: Medical Management01:21

Rheumatic Heart Disease III: Medical Management

480
Rheumatic heart disease (RHD) management can be divided into two main strategies: prevention and long-term management.Primary PreventionPrimary prevention focuses on timely diagnosis and management of group A streptococcal pharyngitis to prevent acute rheumatic fever. The most widely used antibiotic for treating this condition is intramuscular benzathine penicillin G.Acute Rheumatic Fever TreatmentThe primary treatment goal for a patient diagnosed with acute rheumatic fever is to suppress the...
480
Rheumatic Heart Disease IV: Nursing Management01:20

Rheumatic Heart Disease IV: Nursing Management

437
AssessmentA comprehensive assessment is essential in managing a patient with rheumatic heart disease (RHD). Begin with obtaining a detailed medical history, including recent streptococcal infections, a history of rheumatic fever, or previously diagnosed rheumatic heart disease. Assess the patient for symptoms such as fever, chest pain, widespread joint pain (arthralgia), tachycardia, pericardial friction rub, muffled heart sounds, heart murmurs, peripheral edema, subcutaneous nodules, and...
437
T Cell Types and Functions01:24

T Cell Types and Functions

3.2K
When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
3.2K

こちらも読む

関連記事

共著者、ジャーナル、引用グラフによってこの研究に関連する記事。

並び替え
Same author

Introducing EULAR Rheumatology Open (ERO): A New Platform for Advancing Rheumatology Research.

EULAR rheumatology open·2026
Same author

Prognostic Value of Bronchoalveolar Lavage in Systemic Autoimmune Rheumatic Diseases-Associated Interstitial Lung Disease.

Journal of clinical medicine·2026
Same author

Detectable safety gestalt of rheumatoid arthritis treatments from pivotal clinical drug trials.

Rheumatology (Oxford, England)·2026
Same author

Time-resolved immune dynamics in rheumatoid arthritis under methotrexate therapy.

Annals of the rheumatic diseases·2026
Same author

Evaluating machine learning tools to assist title and abstract screening in systematic literature reviews: a report based on the EULAR RA Management Recommendations Task Force.

Annals of the rheumatic diseases·2026
Same author

Chasing the target: reports from the Advances in Targeted Therapies meeting, 2025.

Annals of the rheumatic diseases·2026

関連する実験動画

Updated: Mar 21, 2026

Preliminary Study on Acupuncture Combined with Grain-sized Moxibustion for Treating Rheumatoid Arthritis with Finger Joint Pain
04:50

Preliminary Study on Acupuncture Combined with Grain-sized Moxibustion for Treating Rheumatoid Arthritis with Finger Joint Pain

Published on: May 16, 2025

1.3K

リウマチ性関節炎

Josef S Smolen1, Daniel Aletaha2, Iain B McInnes3

  • 1Division of Rheumatology, Department of Medicine 3, Medical University of Vienna, Vienna, Austria; 2nd Department of Medicine, Hietzing Hospital Vienna, Vienna, Austria.

Lancet (London, England)
|May 10, 2016
PubMed
まとめ
この要約は機械生成です。

リウマチ性関節炎 (RA) の早期診断は,特にリスク因子のある患者にとって,効果的な治療に不可欠です. 現在の戦略は,病気の活性をモニタリングし,様々な病気を修正する抗レウマティック薬を使用することを含みますが,反応しない人に対して新しい治療法が必要です.

さらに関連する動画

Author Spotlight: Implementation of BIVA for Analyzing Disease Risk Factors in Patients with Low Body Cell Mass
07:44

Author Spotlight: Implementation of BIVA for Analyzing Disease Risk Factors in Patients with Low Body Cell Mass

Published on: July 14, 2023

1.8K
An Adoptive Transfer Model of Rheumatoid Arthritis in Mice
07:37

An Adoptive Transfer Model of Rheumatoid Arthritis in Mice

Published on: June 6, 2025

1.4K

関連する実験動画

Last Updated: Mar 21, 2026

Preliminary Study on Acupuncture Combined with Grain-sized Moxibustion for Treating Rheumatoid Arthritis with Finger Joint Pain
04:50

Preliminary Study on Acupuncture Combined with Grain-sized Moxibustion for Treating Rheumatoid Arthritis with Finger Joint Pain

Published on: May 16, 2025

1.3K
Author Spotlight: Implementation of BIVA for Analyzing Disease Risk Factors in Patients with Low Body Cell Mass
07:44

Author Spotlight: Implementation of BIVA for Analyzing Disease Risk Factors in Patients with Low Body Cell Mass

Published on: July 14, 2023

1.8K
An Adoptive Transfer Model of Rheumatoid Arthritis in Mice
07:37

An Adoptive Transfer Model of Rheumatoid Arthritis in Mice

Published on: June 6, 2025

1.4K

科学分野:

  • リウマトロジ
  • 免疫学
  • 遺伝学

背景:

  • リウマチ性関節炎 (RA) は慢性的な炎症性関節疾患で,軟骨/骨の損傷と障害を引き起こす.
  • 早期診断とリスク因子の特定は RA の成功管理に不可欠です
  • 進歩にもかかわらず 多くのRA患者は既存の治療法に反応せず 新しい治療法の必要性を強調しています

研究 の 目的:

  • リウマチ性関節炎 (RA) に関する最新の洞察を提供する.
  • 遺伝学,病因学,病理生理学,流行病学,評価,およびRAの治療戦略をカバーする.
  • RA の患者さんのケアにおける満たされていないニーズを特定する.

主な方法:

  • リウマチ性関節炎 (RA) に関する現在の科学文献のレビュー
  • 遺伝学,病因学,病理生理学,流行病学の分析
  • 現在の評価ツールと治療薬の評価
  • 治療戦略と満たされていないニーズについての議論

主要な成果:

  • RAの管理には 病気の活動量測定と 治療から標的までの戦略が含まれます
  • 従来の生物学的および新しい非生物学的疾患修正抗レウマティック薬が使用されています.
  • 寛解または低疾患の活動が達成された後に投与量を減らすことを検討します.

結論:

  • RAの治療は改善されていますが,治療に反応しない患者には,まだ満たされていない需要が残っています.
  • RAの遺伝学,病理生理学,新しい治療法に関する研究を継続することは不可欠です.
  • RAの治療戦略を最適化するには,早期診断とパーソナライズされた治療を含む包括的なアプローチが必要です.